GO:0050656 3'-phosphoadenosine 5'-phosphosulfate binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0050656 describes the molecular function of binding to 3'-phosphoadenosine 5'-phosphosulfate (PAPS), the universal sulfate donor for sulfotransferases and sulfation reactions.
• PAPS is synthesized by bifunctional PAPS synthases (PAPSS1 and PAPSS2) that contain an ATP sulfurylase domain and an APS kinase domain.
• PAPS binding is essential for sulfotransferase catalysis, and PAPS also allosterically regulates sulfotransferase turnover.
• The PAPS binding site of flavonol 3-sulfotransferase has been mapped by affinity chromatography and 31P NMR, providing a structural paradigm for PAPS recognition.
• PAPS synthases are naturally fragile enzymes stabilized by nucleotide binding, and their dysfunction is linked to genetic deficiency disorders.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal dissection of PAPS-binding proteins in cancer, skeletal disease, and metabolic disorders.
Description
3'-phosphoadenosine 5'-phosphosulfate (PAPS) binding (GO:0050656) is a molecular function that enables proteins to recognize and interact with PAPS, a naturally occurring mixed anhydride that serves as the universal sulfate donor in biological systems. PAPS is generated by PAPS synthases through two sequential reactions: ATP sulfurylase converts ATP and sulfate to adenosine 5'-phosphosulfate (APS), and APS kinase phosphorylates APS to PAPS. Proteins that bind PAPS include sulfotransferases, which transfer the sulfonate group to acceptor molecules, and PAPS synthases themselves, which bind PAPS as a product and regulatory ligand. The importance of PAPS binding extends across eukaryotic biology. Sulfation modifies hormones, neurotransmitters, xenobiotics, glycosaminoglycans, and proteins, influencing their activity, stability, and localization. In plants, PAPS-dependent sulfation contributes to flavonol metabolism and stress responses. In humans, impaired PAPS synthesis or PAPS binding can disrupt skeletal development, drug metabolism, and hormone homeostasis. Because PAPS is energetically expensive to produce, cells tightly regulate PAPS levels and PAPS-binding enzymes, making this GO term a focal point for metabolic engineering and therapeutic targeting. Researchers study GO:0050656 to understand sulfation pathways, to engineer PAPS overproduction in microbial cell factories, and to identify inhibitors of PAPS synthases for cancer therapy. This article synthesizes authoritative QuickGO annotation data and verified PubMed literature to provide a research-grade overview of PAPS binding, its genes, mechanisms, disease links, and experimental models.
3'-phosphoadenosine 5'-phosphosulfate binding At A Glance
| GO ID | GO:0050656 |
|---|---|
| GO term | 3'-phosphoadenosine 5'-phosphosulfate binding |
| Ontology | molecular_function |
| Synonym | PAPS binding; 3'-phosphoadenosine 5'-phosphosulphate binding; 3'-phosphoadenylyl-sulfate binding; adenosine 3'-phosphate 5'-phosphosulfate binding; phosphoadenosine phosphosulfate binding |
| Major function | Non-covalent recognition of PAPS, the universal sulfate donor, by sulfotransferases and PAPS synthases |
| Definition source | QuickGO definition: Binding to 3'-phosphoadenosine 5'-phosphosulfate (PAPS), a naturally occurring mixed anhydride; intermediate in formation of sulfo compounds |
| Related enzymes | PAPS synthases (PAPSS1, PAPSS2), sulfotransferases (SULT family), flavonol 3-sulfotransferase |
| Pathological relevance | PAPS synthase deficiency, skeletal dysplasia, cancer metabolism, drug sulfation |
| Research applications | Enzyme kinetics, structural biology, metabolic engineering, CRISPR knockout/knock-in models |
What Is GO:0050656?
GO:0050656 (3'-phosphoadenosine 5'-phosphosulfate binding) is defined by QuickGO as the binding to 3'-phosphoadenosine 5'-phosphosulfate (PAPS), a naturally occurring mixed anhydride that is an intermediate in the formation of a variety of sulfo compounds in biological systems. In practical terms, this molecular function describes any protein domain or site that non-covalently recognizes PAPS, whether as a substrate for sulfotransferases, a product/regulatory ligand for PAPS synthases, or a cofactor for other sulfation-dependent enzymes.
Why Is 3'-phosphoadenosine 5'-phosphosulfate binding Important in Cell Biology?
PAPS binding is central to sulfur metabolism because PAPS is the obligate sulfate donor for all sulfotransferase reactions in eukaryotes. Without efficient PAPS binding, cells cannot sulfonate hormones, neurotransmitters, glycosaminoglycans, or xenobiotics, leading to disrupted endocrine signaling, impaired detoxification, and defective extracellular matrix formation. Moreover, PAPS binding regulates enzyme turnover: PAPS allosterically modulates sulfotransferase stability, linking donor availability to catalytic output. In biotechnology, engineering PAPS binding and synthesis enhances production of sulfated compounds in yeast and other hosts. In medicine, PAPS synthase mutations cause genetic deficiency syndromes, and PAPS-binding enzymes are candidate targets for cancer therapy and drug metabolism modulation.
• PAPS binding enables sulfotransferases to transfer sulfate to hormones, neurotransmitters, and drugs, controlling their biological activity.
• PAPS synthases require PAPS binding for product feedback and nucleotide stabilization, and their dysfunction causes skeletal and metabolic disorders.
• The PAPS binding site of flavonol 3-sulfotransferase has been structurally characterized, informing plant sulfation biology.
• PAPS allosterically regulates sulfotransferase turnover, connecting donor supply to enzyme degradation.
• PAPS synthase 1 (PAPSS1) is a potential cancer target, and phytochemical inhibitors have been explored.
• Structure-guided engineering of PAPSS1 enhances PAPS biosynthesis for industrial applications.
• Synthetic transcription factors can fine-tune PAPS production in yeast, demonstrating pathway control.
• PAPS binding is relevant to drug metabolism, as sulfation inactivates or activates xenobiotics.
• Defects in PAPS synthesis lead to impaired sulfation of glycosaminoglycans, affecting cartilage and bone.
• CRISPR models of PAPS-binding genes enable causal studies in development, cancer, and metabolism.
Molecular Mechanism of 3'-phosphoadenosine 5'-phosphosulfate binding
PAPS Synthesis and Donor Availability
In simple terms: Cells first make PAPS, the sulfate donor, before any protein can bind it.
PAPS is synthesized by bifunctional PAPS synthases (PAPSS1 and PAPSS2) that contain an ATP sulfurylase domain and an APS kinase domain. The ATP sulfurylase domain converts ATP and sulfate to APS, and the APS kinase domain phosphorylates APS to PAPS. Human PAPS synthase is a naturally fragile enzyme that is stabilized by nucleotide binding, and its ATP sulfurylase domain structure has been characterized. Because PAPS synthesis consumes two ATP equivalents, cells regulate PAPS levels tightly.
PAPS Recognition by Sulfotransferases
In simple terms: Sulfotransferases grab PAPS and transfer its sulfate group to target molecules.
Sulfotransferases bind PAPS in a conserved pocket and catalyze the transfer of the sulfonate group to hydroxyl or amine acceptors, releasing 3'-phosphoadenosine 5'-phosphate (PAP). The PAPS binding site of flavonol 3-sulfotransferase was studied by affinity chromatography and 31P NMR, revealing key residues involved in PAPS recognition. PAPS binding is essential for catalysis, and mutations in the binding pocket abolish sulfotransferase activity.
Allosteric Regulation by PAPS
In simple terms: PAPS can also act as a signal that controls how long sulfotransferases survive in the cell.
PAPS allosterically regulates sulfotransferase turnover, meaning that binding of PAPS to sulfotransferases influences their stability and degradation. This feedback mechanism links the availability of the sulfate donor to the amount of active enzyme, preventing wasteful accumulation of sulfotransferases when PAPS is scarce. Such regulation is critical for maintaining sulfation homeostasis in tissues exposed to fluctuating hormone and xenobiotic levels.
Structural Basis of PAPS Binding
In simple terms: The shape of the PAPS-binding pocket determines how tightly and specifically PAPS is held.
Structural studies of PAPS synthases and sulfotransferases have revealed that PAPS binds through a network of hydrogen bonds and electrostatic interactions with conserved arginine, lysine, and serine residues. The ATP sulfurylase domain of human PAPS synthase undergoes conformational changes upon nucleotide binding, which stabilizes the enzyme. Structure-guided engineering of PAPSS1 has been used to enhance PAPS biosynthesis, demonstrating that the binding pocket is amenable to rational modification.
PAPS Binding in Metabolic Engineering
In simple terms: Scientists tweak PAPS-binding proteins to make more sulfated products in yeast and other cells.
Fine-tuned synthetic transcription factors have been used to control PAPS production in yeast, enabling improved biosynthesis of sulfated compounds. Structure-guided engineering of human PAPSS1 enhances PAPS biosynthesis, which can be coupled to sulfotransferase reactions for industrial production of sulfated molecules. These approaches rely on optimizing PAPS binding and catalytic efficiency of PAPS synthases and sulfotransferases.
Key Genes Involved in GO:0050656 3'-phosphoadenosine 5'-phosphosulfate binding
The following genes encode proteins that bind PAPS or regulate PAPS synthesis, as supported by the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PAPSS1 | Bifunctional PAPS synthase; ATP sulfurylase and APS kinase domains | Target for cancer therapy; engineered for enhanced PAPS biosynthesis |
| PAPSS2 | Bifunctional PAPS synthase; major isoform in cartilage and bone | Mutations cause skeletal dysplasia and PAPS deficiency |
| SULT1A1 | Cytosolic sulfotransferase that binds PAPS to sulfate phenols and hormones | Drug metabolism and hormone regulation |
| SULT1E1 | Estrogen sulfotransferase; binds PAPS to sulfate estrogens | Endocrine signaling and cancer |
| SULT2A1 | Bile acid and steroid sulfotransferase; PAPS-dependent | Liver metabolism and detoxification |
| SULT1B1 | Thyroid hormone sulfotransferase; PAPS-binding enzyme | Thyroid hormone homeostasis |
| SULT4A1 | Brain-specific sulfotransferase; binds PAPS | Neurotransmitter sulfation and neurodegeneration |
| F3ST | Flavonol 3-sulfotransferase; PAPS-binding site characterized | Plant sulfation and flavonol metabolism |
| PAPSS1 (ATP sulfurylase domain) | Catalyzes APS formation from ATP and sulfate | Structural studies of PAPS binding |
| PAPSS2 (APS kinase domain) | Phosphorylates APS to PAPS | Genetic deficiency and skeletal disease |
| SULT1C2 | Sulfotransferase with PAPS binding | Xenobiotic metabolism |
| SULT1A3 | Dopamine sulfotransferase; PAPS-dependent | Neurotransmitter regulation |
| SULT2B1 | Cholesterol sulfotransferase; binds PAPS | Skin barrier and steroid metabolism |
| SULT6B1 | Sulfotransferase with PAPS binding | Orphan sulfation pathways |
| PAPSS1 variants | Engineered PAPS synthases with altered binding | Biosynthesis optimization |
| Synthetic transcription factors | Regulate PAPS pathway genes in yeast | Metabolic engineering |
| PAPSS2 variants | Disease-associated mutations affecting PAPS binding | Skeletal dysplasia models |
How Is 3'-phosphoadenosine 5'-phosphosulfate binding Regulated?
PAPS binding and PAPS synthesis are regulated at multiple levels. PAPS synthases are stabilized by nucleotide binding, and their fragility means that mutations or environmental stress can reduce PAPS production. PAPS allosterically regulates sulfotransferase turnover, providing feedback control that matches enzyme levels to donor availability. In yeast, synthetic transcription factors can fine-tune expression of PAPS pathway genes, demonstrating that transcriptional control is a key regulatory node. Additionally, structure-guided engineering of PAPSS1 has shown that the ATP sulfurylase domain can be modified to enhance PAPS biosynthesis, indicating that intrinsic catalytic regulation is tunable.
3'-phosphoadenosine 5'-phosphosulfate binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PAPSS2 | Skeletal dysplasia, androgen excess due to PAPS deficiency | Knockout or point-mutation knock-in in chondrocytes |
| PAPSS1 | Cancer metabolism, potential therapeutic target | CRISPR knockout in cancer cell lines; overexpression for resistance studies |
| SULT1E1 | Estrogen-dependent cancers, endocrine disruption | Knockout and overexpression in breast cancer cells |
| SULT4A1 | Neurodegeneration, brain sulfation defects | Knockout in neuronal cells; knock-in of patient variants |
| SULT2A1 | Liver disease, bile acid metabolism disorders | Knockout in hepatocytes; PAPS-binding point mutants |
PAPS Synthase Deficiency and Skeletal Dysplasia
Mutations in PAPSS2, which encodes a PAPS synthase, cause a genetic deficiency characterized by impaired sulfation of glycosaminoglycans, leading to skeletal dysplasia and androgen excess. Because PAPS binding is essential for PAPSS2 function, disease-associated mutations often affect the ATP sulfurylase or APS kinase domains, reducing PAPS production. These findings establish PAPS binding as a critical node in human skeletal and endocrine health.
Cancer Metabolism and PAPSS1 Targeting
PAPSS1 is overexpressed in some cancers and is considered a potential therapeutic target because PAPS is required for sulfation of growth factors and xenobiotics. Phytochemical inhibitors of PAPSS1 have been explored in silico and in vitro, suggesting that disrupting PAPS binding or synthesis could impair tumor metabolism. Structure-guided engineering of PAPSS1 also provides tools to study its role in cancer cell proliferation.
Drug Metabolism and Sulfation
Many drugs and endogenous compounds are inactivated or activated by sulfotransferases that bind PAPS. Genetic variation in sulfotransferases and PAPS synthases can alter drug clearance and toxicity, making PAPS binding a determinant of interindividual variability in drug response. PAPS allosteric regulation of sulfotransferase turnover further modulates drug metabolism capacity.
From 3'-phosphoadenosine 5'-phosphosulfate binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of PAPS binding abolish sulfotransferase activity? | CRISPR knockout of the PAPS-binding domain in SULT genes |
| How do disease-associated PAPSS2 mutations affect PAPS synthesis? | Point-mutation knock-in of patient variants in cell lines |
| Can engineered PAPSS1 improve PAPS production? | Knock-in of structure-guided mutations or overexpression of PAPSS1 variants |
| What is the role of PAPS binding in cancer cell proliferation? | CRISPR knockout or inducible overexpression of PAPSS1 in cancer cells |
| How do synthetic transcription factors control PAPS pathway flux? | Knock-in or overexpression of synthetic transcription factors in yeast |
| Does PAPS allosteric regulation affect sulfotransferase stability? | Point mutations in the PAPS-binding site combined with turnover assays |
How to Study the 3'-phosphoadenosine 5'-phosphosulfate binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Affinity chromatography | PAPS binding affinity and specificity | Purification and characterization of sulfotransferases |
| 31P NMR | Conformational changes and binding site environment | Mapping PAPS binding site in flavonol 3-sulfotransferase |
| Enzyme kinetics | Catalytic efficiency of PAPS synthesis or transfer | PAPS synthase and sulfotransferase assays |
| X-ray crystallography | Three-dimensional structure of PAPS-protein complexes | Structure-guided engineering of PAPSS1 |
| CRISPR knockout screens | Genes required for PAPS-dependent growth | Cancer and metabolic pathway discovery |
| Point-mutation knock-in | Effect of specific residues on PAPS binding | Disease variant modeling |
| Overexpression | Gain-of-function effects on PAPS production | Metabolic engineering in yeast |
| Metabolomics | PAPS and sulfated metabolite levels | Pathway flux analysis |
Biochemical Assays for PAPS Binding
PAPS binding can be measured using affinity chromatography and 31P NMR, as demonstrated for flavonol 3-sulfotransferase. These methods reveal dissociation constants and conformational changes upon PAPS binding. Enzyme kinetics with radiolabeled PAPS or PAPS analogs can quantify sulfotransferase activity and PAPS synthase catalysis.
Structural Biology of PAPS-Binding Proteins
X-ray crystallography and cryo-EM have been used to determine structures of PAPS synthases and sulfotransferases in complex with PAPS or nucleotide analogs. These structures identify key contact residues and guide mutagenesis. Structure-guided engineering of PAPSS1 has successfully enhanced PAPS biosynthesis, validating structural insights.
CRISPR Screens and Functional Genomics
CRISPR knockout screens can identify genes required for PAPS-dependent sulfation and cell fitness. Point-mutation knock-in models allow precise testing of PAPS-binding residues in disease variants. Overexpression models can assess gain-of-function effects of PAPS synthases or sulfotransferases.
Metabolic Engineering and Flux Analysis
Synthetic transcription factors and pathway engineering in yeast enable fine-tuned control of PAPS production. Metabolomics and flux analysis can quantify PAPS and sulfated products, linking PAPS binding efficiency to pathway output. These approaches are valuable for industrial biosynthesis of sulfated compounds.
How CRISPR Can Be Used to Study GO:0050656 3'-phosphoadenosine 5'-phosphosulfate binding
Knockout
CRISPR knockout of PAPS-binding genes such as PAPSS1, PAPSS2, or sulfotransferases can abolish sulfation pathways, revealing their role in cell proliferation, drug metabolism, and development. Knockout models are essential for causal inference and for validating therapeutic targets.
Point Mutation
Point-mutation knock-in of disease-associated variants in PAPSS2 or sulfotransferase PAPS-binding pockets allows precise testing of how single amino acid changes affect PAPS binding and catalysis. These models mimic human genetic deficiencies and can be used for drug screening.
Knock-in
Knock-in of engineered PAPSS1 variants with enhanced PAPS binding can boost PAPS biosynthesis for industrial or therapeutic applications. Tagged knock-in of PAPS-binding proteins enables imaging and interactome studies.
Overexpression
Overexpression of PAPS synthases or sulfotransferases increases sulfation capacity and can be used to study PAPS allosteric regulation and metabolic flux. In yeast, overexpression combined with synthetic transcription factors fine-tunes PAPS production.
How EDITGENE Supports 3'-phosphoadenosine 5'-phosphosulfate binding Research
Researchers studying 3'-phosphoadenosine 5'-phosphosulfate binding-related genes often need to determine whether a candidate gene is causally involved in sulfation, disease, or metabolic engineering. EDITGENE provides CRISPR-based cell models and screening services to accelerate this discovery.
Contact EDITGENE today to design your custom CRISPR model for 3'-phosphoadenosine 5'-phosphosulfate binding research.
Frequently Asked Questions About 3'-phosphoadenosine 5'-phosphosulfate binding
What is 3'-phosphoadenosine 5'-phosphosulfate binding?
It is the molecular function GO:0050656, defined as binding to PAPS, the universal sulfate donor used by sulfotransferases and PAPS synthases.
What genes are involved in 3'-phosphoadenosine 5'-phosphosulfate binding?
Key genes include PAPSS1, PAPSS2, and sulfotransferases such as SULT1A1, SULT1E1, SULT2A1, and SULT4A1.
What is PAPS and why is it important?
PAPS is a mixed anhydride that donates sulfate groups to hormones, neurotransmitters, drugs, and glycosaminoglycans, making it essential for metabolism and signaling.
How is PAPS synthesized?
PAPS is synthesized by bifunctional PAPS synthases: the ATP sulfurylase domain forms APS from ATP and sulfate, and the APS kinase domain phosphorylates APS to PAPS.
What diseases are linked to PAPS binding defects?
PAPSS2 mutations cause skeletal dysplasia and androgen excess, while PAPSS1 is a candidate cancer target and sulfotransferase variants affect drug metabolism.
How do researchers study PAPS binding?
Methods include affinity chromatography, 31P NMR, enzyme kinetics, X-ray crystallography, CRISPR knockout screens, and metabolomics.
Can CRISPR be used to study PAPS-binding genes?
Yes, CRISPR knockout, point-mutation knock-in, and overexpression models are widely used to dissect PAPS pathway function and disease variants.
What is the role of PAPS in drug metabolism?
Sulfotransferases bind PAPS to sulfate drugs and xenobiotics, altering their activity and clearance, which affects drug efficacy and toxicity.
How is PAPS production regulated?
PAPS synthases are stabilized by nucleotide binding, PAPS allosterically regulates sulfotransferase turnover, and synthetic transcription factors can fine-tune pathway expression.
Why is PAPS binding important for biotechnology?
Engineering PAPS binding and synthesis enhances production of sulfated compounds in yeast and other hosts for industrial and pharmaceutical applications.
Conclusion
GO:0050656 (3'-phosphoadenosine 5'-phosphosulfate binding) is a fundamental molecular function that governs sulfation in all eukaryotes. From PAPS synthesis by PAPSS1 and PAPSS2 to sulfotransferase catalysis and allosteric regulation, PAPS binding controls hormone metabolism, drug detoxification, skeletal development, and cancer cell biology. Advances in structural biology and CRISPR engineering continue to reveal how PAPS-binding proteins can be targeted or optimized for therapeutic and industrial applications. Researchers can now use knockout, point-mutation, knock-in, and overexpression models to causally test PAPS-binding genes in disease and metabolic engineering. EDITGENE provides end-to-end CRISPR services to accelerate these discoveries.
References
- 1. Venkatachalam KV. 2003. Human 3'-phosphoadenosine 5'-phosphosulfate (PAPS) synthase: biochemistry, molecular biology and genetic deficiency.. IUBMB Life 55(1):1-11 PMID: 12716056
- 2. Wang T et al.. 2014. 3'-Phosphoadenosine 5'-phosphosulfate allosterically regulates sulfotransferase turnover.. Biochemistry 53(44):6893-900 PMID: 25314023
- 3. Marsolais F et al.. 1999. 3'-Phosphoadenosine 5'-phosphosulfate binding site of flavonol 3-sulfotransferase studied by affinity chromatography and 31P NMR.. Biochemistry 38(13):4066-71 PMID: 10194320
- 4. Venkatachalam KV et al.. 2025. Structure/function of ATP sulfurylase domain of human 3'-phosphoadenosine 5'-phosphosulfate synthase (hPAPSS).. Biochem Biophys Rep 41:101892 PMID: 39760098
- 5. Alharbi B et al.. 2024. Exploring the potential of phytochemicals as inhibitors of 3'-phosphoadenosine 5'-phosphosulfate synthase 1 targeting cancer therapy.. J Biomol Struct Dyn 42(6):3193-3203 PMID: 37184152
- 6. van den Boom J et al.. 2012. 3'-Phosphoadenosine 5'-phosphosulfate (PAPS) synthases, naturally fragile enzymes specifically stabilized by nucleotide binding.. J Biol Chem 287(21):17645-17655 PMID: 22451673
- 7. Zhang R et al.. 2025. Structure-Guided Engineering of Human 3'-Phosphoadenosine-5'-phosphosulfate Synthetase 1 to Enhance Biosynthesis of PAPS.. J Agric Food Chem 73(46):29683-29695 PMID: 41198566
- 8. Borah M et al.. 2026. Fine-tuned synthetic transcription factors for production of 3'-phosphoadenosine-5'-phosphosulfate in yeast.. Microb Cell Fact 25(1) PMID: 42509562
